Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers

American Journal of Tropical Medicine and Hygiene

Volumn 86, Issue 3, 2012, Pages 489-495

  Morris, Carrie A ^a   Lopez Lazaro, Luis ^b   Jung, Donald ^c   Methaneethorn, Janthima ^a   Duparc, Stephan ^d   Borghini Fuhrer, Isabelle ^d   Pokorny, Rolf ^b   Shin, Chang Sik ^e   Fleckenstein, Lawrence ^a  

^a UNIVERSITY OF IOWA   (United States)

^b Covance Clinical Research Unit AG ^*  (Switzerland)

^c Pharmaceutical Research Services   (United States)

^d International Center   (Switzerland)

^e Shin Poong Pharmaceuticals Co Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; ARTESUNATE PLUS PYRONARIDINE; CYTOCHROME P450 2D6; DIHYDROARTEMISININ; PYRONARIDINE; RITONAVIR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; GENOTYPE; HEADACHE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PULSE RATE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTIMALARIALS; AREA UNDER CURVE; ARTEMISININS; DRUG INTERACTIONS; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; NAPHTHYRIDINES; RITONAVIR; YOUNG ADULT;

ARTESUNATE;

EID: 84859561800     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2012.11-0558     Document Type: Article

References (16)

1. Abbott Laboratories, 2010. Ritonavir (Norvir) European medicines agency summary of product characteristics. London, UK: Abbott Laboratories.
2. Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, Touw DJ, Wieling J, Hekster YA, Burger DM, 2005. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther 78: 664-674. (Pubitemid 41773642)
3. Sankatsing SU, Beijnen JH, Schinkel AH, Lange JM, Prins JM, 2004. P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother 48: 1073-1081. (Pubitemid 38405457)
4. Foisy MM, Yakiwchuk EM, Hughes CA, 2008. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 42: 1048-1059.
5. Ilett KF, Ethell BT, Maggs JL, Davis TM, Batty KT, Burchell B, Binh TQ, Thu le TA, Hung NC, Pirmohamed M, Park BK, Edwards G, 2002. Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos 30: 1005-1012.
6. Naik H, Murry DJ, Kirsch LE, Fleckenstein L, 2005. Development and validation of a high-performance liquid chromatographymass spectroscopy assay for determination of artesunate and dihydroartemisinin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 816: 233-242. (Pubitemid 40143511)
7. Naik H, Imming P, Schmidt MS, Murry DJ, Fleckenstein L, 2007. Development and validation of a liquid chromatography-mass spectrometry assay for the determination of pyronaridine in human blood for application to clinical pharmacokinetic studies. J Pharm Biomed Anal 45: 112-119. (Pubitemid 47375003)
8. World Health Organization, 2011. Guidelines for the Treatment of Malaria. Second edition. Geneva, Switzerland: World Health Organization.
9. Food and Drug Administration, Center for Drug Evaluation and Research, 2011. Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation. Rockville, MD: Books LLC.
10. Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L, 2011. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J 10: 263.
11. German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D, Charlebois E, Hanpithakpong W, Lindegardh N, Aweeka FT, 2009. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 51: 424-429.
12. Qi J, Wang S, Liu G, Peng H, Wang J, Zhu Z, Yang C, 2004. Pyronaridine, a novel modulator of P-glycoprotein-mediated multidrug resistance in tumor cells in vitro and in vivo. Biochem Biophys Res Commun 319: 1124-1131. (Pubitemid 38759528)
13. Qi J, Yang CZ, Wang CY, Wang SB, Yang M, Wang JH, 2002. Function and mechanism of pyronaridine: a new inhibitor of P-glycoprotein-mediated multidrug resistance. Acta Pharmacol Sin 23: 544-550. (Pubitemid 34602096)
14. Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A, Valdes J, Smith J, Erdman K, Lyons N, Niu P, Decourt JP, Fourtillan JB, Girault J, Leonard JM, 1997. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 41: 898-905. (Pubitemid 27194157)
15. Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Pyae Phyo A, Valecha N, Rao BH, Tjitra E, Purnama A, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L, 2011. Pyronaridineartesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS ONE 6: e14501.
16. Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SS, Bustos DG, Tjitra E, Bedu-Addo G, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L, Pyronaridine-artesunate Study Team, 2010. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemetherlumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 375: 1457-1467.